Eligibility criteria for intraoperative radiotherapy for breast cancer: study employing 12,025 patients treated in two cohorts

Table 4 Comparison of survival without locoregional recurrence of the G3S cohort

		R1E	R1nE	T1E	T1nE	T1E-R1E
	Number	1589	5982	4031	3540	2442
3 years	%	99.4%	98.3%	98.9%	98.2%	98.6%
	Standard error	0.2	0.2	0.2	0.2	0.3
	exposed to the risk	1347	4554	3109	2792	1761
5 years	%	98%	97.1%	97.6%	97%	97.2%
	Standard error	0.4	0.2	0.3	0.3	0.4
	exposed to the risk	835	2886	1921	1800	1085
7 years	%	97.1%	94.8%	96.4%	94.2%	95.9%
	Standard error	0.6	0.5	0.4	0.6	0.6
	exposed to the risk	243	869	556	556	312
10 years	%	95.5%	91.4%	93.9%	90.6%	92.9%
	Standard error	1.3	1.2	1.4	1.4	2.3
	exposed to the risk	11	27	21	17	9
Log rank			0.011		0.009	0.125*

*R1E vs (T1E-R1E), no significant difference.
Key: RE (eligible for RIOP), R1nE (not eligible for RIOP), T1E (eligible for TARGIT A) T1nE (not eligible for TARGIT A).
*Locoregional recurrence significantly more frequent in the case of over-expression of Her2: only for patients not eligible for TARGIT A and RIOP (selection of the most unfavorable cases).

ISSN: 1471-2407